#USA #Seattle #Atossa Therapeutics #Z-Endoxifen #McCune-Albright

Atossa Therapeutics Presents Innovative Data on (Z)-Endoxifen

Atossa Therapeutics, Inc., a company focused on developing groundbreaking therapies for oncology and other significant clinical challenges, has unveiled new findings on July 21, 2026. These findings, presented at the AACR Special Conference on Rare Cancers in Vancouver, focus on the therapeutic potential of (Z)-endoxifen for treating McCune-Albright Syndrome (MAS).

Conference Presentation Details

The presentation featured a poster titled "Dual estrogen receptor and PKC-β signaling modulation by (Z)-Endoxifen: A mechanism-driven therapeutic strategy for estrogen-driven pathology in McCune-Albright Syndrome." This session highlighted the dual mechanisms by which (Z)-endoxifen may impact estrogen-driven conditions prevalent in MAS, specifically targeting the blockade of estrogen receptor-mediated transcription and the inhibition of the PKC-β/AKT pathways.

Key Findings

Recent research underscores how (Z)-endoxifen addresses essential gaps in treatments for MAS, particularly for those experiencing Peripheral Precocious Puberty (PPP). The analysis reveals a broad mechanism of action that combines estrogen suppression and the affecting of proliferative signaling pathways that too often lead to estrogen-induced pathology. This dual-action profile positions (Z)-endoxifen as a potentially groundbreaking therapeutic for patients suffering from this rare syndrome.

Dr. Steven C. Quay, President and CEO of Atossa, emphasized the relevance of these findings, noting that conventional therapies mainly focusing on estrogen production may not adequately suppress the downstream effects of estrogen signaling. This underscores the value of a multi-faceted approach in addressing the complexities of MAS-related conditions.

Insights Into McCune-Albright Syndrome

McCune-Albright Syndrome is characterized by a triad of symptoms, including Polyostotic Fibrous Dysplasia, Café-au-lait Spots, and Hyperfunctioning Endocrinopathies - a spectrum that often leads to precocious puberty in children, especially girls. The intricacies involved in diagnosing and treating this rare genetic disorder highlight a considerable unmet medical need.

Most importantly, patients with MAS may face serious complications, such as accelerated physical growth and developmental issues, unless timely and effective therapeutic strategies are deployed. Atossa's focus on (Z)-endoxifen could lay the groundwork for revolutionary treatment pathways that better manage this syndrome's symptoms.

Conclusion

Atossa Therapeutics continues to demonstrate its commitment to addressing rare diseases with innovative approaches. The company is actively developing (Z)-endoxifen as a leading candidate to tackle the complexities of estrogen-driven medical conditions like McCune-Albright Syndrome. With ongoing research and clinical trials, the potential for this therapy may provide new hope for patients in need of effective treatment solutions.

For more information about Atossa Therapeutics and their clinical developments, visit Atossa Therapeutics' website.